Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Current opinion in investigational drugs

• Publication date

  2007-03-01

• Fields of study

  Medicine, Environmental Science

• Identifiers
  PMID 17408118
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.

  2007cited by this paper
• Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia.

  2006cited by this paper
• Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.

  2006cited by this paper
• Endothelial Nitric Oxide Synthase Polymorphisms Do Not Influence Pulmonary Artery Systolic Pressure at Altitude

  2006cited by this paper
• Both Tadalafil and Dexamethasone May Reduce the Incidence of High-Altitude Pulmonary Edema

  2006cited by this paper
• Role of Endothelin-1 in Exposure to High Altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) Study

  2006cited by this paper
• Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond

  2006cited by this paper
• Physiological aspects of high-altitude pulmonary edema.

  2005cited by this paper
• Effects of Sildenafil on the Human Response to Acute Hypoxia and Exercise

  2005cited by this paper
• Treatment of pulmonary hypertension in the general adult intensive care unit: a role for oral sildenafil?

  2005cited by this paper
• Phosphodiesterase type 5 and high altitude pulmonary hypertension

  2005cited by this paper
• Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.

  2005cited by this paper
• Hypoxia impairs systemic endothelial function in individuals prone to high-altitude pulmonary edema.

  2005cited by this paper
• Oral sildenafil reduces pulmonary hypertension after cardiac surgery.

  2005cited by this paper
• Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension.

  2005cited by this paper
• High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.

  2005cited by this paper
• The Clinical Pharmacokinetics of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction

  2005cited by this paper
• Past, present, and future: a 7‐year update of Viagra® (sildenafil citrate)

  2005cited by this paper
• Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats.

  2004cited by this paper
• The Role of the NO Axis and its Therapeutic Implications in Pulmonary Arterial Hypertension

  2004cited by this paper
• The Physiologic Basis of High-Altitude Diseases

  2004cited by this paper
• Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects.

  2004cited by this paper
• Sildenafil Increased Exercise Capacity during Hypoxia at Low Altitudes and at Mount Everest Base Camp

  2004cited by this paper
• Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.

  2004cited by this paper
• Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.

  2004cited by this paper
• Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension.

  2003cited by this paper
• Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality.

  2002cited by this paper
• Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension.

  2002cited by this paper
• Pathogenesis of high-altitude pulmonary edema: inflammation is not an etiologic factor.

  2002cited by this paper
• A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction.

  2002cited by this paper
• Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.

  2002cited by this paper
• Salmeterol for the prevention of high-altitude pulmonary edema.

  2002cited by this paper
• Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension: Comparison With Inhaled Nitric Oxide

  2002cited by this paper
• Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension

  2001cited by this paper
• Hypoxia decreases exhaled nitric oxide in mountaineers susceptible to high-altitude pulmonary edema.

  2001cited by this paper
• High-altitude illness.

  2001cited by this paper
• Cyclic nucleotide phosphodiesterases: relating structure and function.

  2001cited by this paper
• Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension

  2001cited by this paper
• Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension

  2001cited by this paper
• High-Altitude Pulmonary Edema Is Initially Caused by an Increase in Capillary Pressure

  2001cited by this paper
• Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study

  2001cited by this paper
• Transepithelial sodium and water transport in the lung. Major player and novel therapeutic target in pulmonary edema.

  2001cited by this paper
• Stress Doppler echocardiography for identification of susceptibility to high altitude pulmonary edema.

  2000cited by this paper
• Sildenafil Is a Pulmonary Vasodilator in Awake Lambs with Acute Pulmonary Hypertension

  2000cited by this paper
• Nitric oxide synthase in pulmonary hypertension: lessons from knockout mice.

  2000cited by this paper
• Effects of sildenafil citrate on human hemodynamics.

  1999cited by this paper
• Regulation of pulmonary circulation by alveolar oxygen tension via airway nitric oxide.

  1999cited by this paper
• Molecular Basis of Cell-Specific Endothelial Nitric Oxide Synthase Expression in Airway Epithelium • 263

  1998cited by this paper
• Inflammatory cytokines in BAL fluid and pulmonary hemodynamics in high-altitude pulmonary edema.

  1998cited by this paper
• Inhaled nitric oxide for high-altitude pulmonary edema.

  1996cited by this paper
• Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs.

  1995cited by this paper
• Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms.

  1995cited by this paper
• High altitude pulmonary oedema: still a place for controversy?

  1995cited by this paper
• Pathogenesis of high-altitude pulmonary oedema: direct evidence of stress failure of pulmonary capillaries.

  1995cited by this paper
• Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase.

  1994cited by this paper
• Nifedipine does not prevent acute mountain sickness.

  1994cited by this paper
• Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors.

  1994cited by this paper
• The L-arginine-nitric oxide pathway.

  1993cited by this paper
• Prevention and Treatment of High Altitude Pulmonary Edema by a Calcium Channel Blocker

  1992cited by this paper
• Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues.

  1991cited by this paper
• Prevention of high-altitude pulmonary edema by nifedipine.

  1991cited by this paper
• Inhibition of hypoxic pulmonary vasoconstriction by nifedipine.

  1982cited by this paper
• Abnormal Circulatory Responses to High Altitude in Subjects with a Previous History of High‐Altitude Pulmonary Edema

  1971cited by this paper
• The influence of short periods of induced acute anoxia upon pulmonary artery pressures in man.

  1947cited by this paper

• A case of fulminant neurogenic pulmonary edema successfully treated with phenoxybenzamine and sildenafil

  2024cites this paper
• PDE5 inhibitors: breaking new grounds in the treatment of COVID-19

  2023cites this paper
• PDE5 inhibitors: breaking new grounds in the treatment of COVID-19

  2023cites this paper
• Treatment of Cardiovascular Dysfunction With PDE5-Inhibitors – Temperature Dependent Effects on Transport and Metabolism of cAMP and cGMP

  2021cites this paper
• Interventions for treating acute high altitude illness.

  2018cites this paper
• Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs.

  2017cites this paper
• Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan

  2016cites this paper
• CURRENT AND EMERGING USES OF PHOSPHODIESTERASE 5 INHIBITORS.

  2014cites this paper
• High-Altitude Medicine: The Path from Genomic Insight to Clinical Applications

  2014cites this paper
• Clinical and molecular genetics of the phosphodiesterases (PDEs).

  2014cites this paper
• Prevention, assessment and management of altitude sickness

  2013cites this paper
• Retinal Vessel Tortuosity in Response to Hypobaric Hypoxia

  2012cites this paper
• Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

  2012cites this paper
• Interventions for preventing high altitude illness

  2012cites this paper
• High Altitude Pulmonary Oedema

  2011cites this paper
• Can migraine prophylaxis prevent acute mountain sickness at high altitude?

  2011cites this paper
• Cardiovascular aspects of sexual medicine.

  2010cites this paper
• Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs.

  2010cites this paper
• Cardiovascular effects of phosphodiesterase type 5 inhibitors.

  2009cites this paper
• High Altitude Adaptation: Genetic Perspectives

  2008cites this paper
• Phosphodiesterase type 5 inhibitors: state of the therapeutic class.

  2007cites this paper
• The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development.

  2007cites this paper
• Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications.

  2007cites this paper